Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 832 participants.

Also called NCT06134622

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 832 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06134622
Other papers using this trial's data
  • Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke The New England journal of medicine, 2025-09-25 DOI, PubMed 40616232

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06134622. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-14 (actual); primary completion 2024-09-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)
Acronym
ASSET-IT
Condition
Acute Ischemic Stroke
Intervention (Drug)
Intravenous thrombolysis plus tirofiban
Intervention (Drug)
Intravenous thrombolysis plus placebo
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China (class: other)

Record details

Record id
cardio:ct-nct06134622
Content hash
53783fa7d8104d2289e81df453750ae0206a3fac7665468710bf6ba5a0d96acd